Cellerant Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cellerant Therapeutics's estimated annual revenue is currently $930k per year.
- Cellerant Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Cellerant Therapeutics has 6 Employees.
- Cellerant Therapeutics grew their employee count by 0% last year.
Cellerant Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Cellerant Therapeutics?
Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s romyelocel-L is a universal cell therapy which does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. In a randomized, controlled Phase 2 clinical trial in AML patients, romyelocel-L reduced infections and days in hospital. Cellerant is developing two novel antibody drug-conjugate (ADC) products: CLT030 to treat AML by selectively targeting and killing leukemic stem and blast cells, and CSC012-ADC for hematologic malignancies and solid tumor indications.
keywords:N/A
N/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Carlos
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A |
#2 | $0.1M | 6 | -33% | $12M |
#3 | $0.4M | 6 | 0% | N/A |
#4 | $0.9M | 6 | 0% | N/A |
#5 | $0.2M | 6 | -33% | $45.2M |